IL22RA1: Potential Drug Target and Biomarker for Various Diseases

Target Name: IL22RA1

NCBI ID: G58985

IL22RA1

IL22RA1: Potential Drug Target and Biomarker for Various Diseases

IL22RA1 (Interleukin-22 receptor alpha chain 1) is a protein that is expressed in various tissues throughout the body, including the immune system, skin, and hair. It is a member of the cytokine receptor family 2, which plays a crucial role in the regulation of immune responses and inflammation. The IL22RA1 protein has been identified as a potential drug target and a biomarker for various diseases, including cancer, autoimmune disorders, and skin diseases.

The IL22RA1 protein is a transmembrane protein that is expressed in the cytoplasm of various cell types. It consists of an extracellular domain, a transmembrane domain, and an intracellular domain. The extracellular domain is the portion of the protein that is exposed to the outside of the cell, and it contains a conserved region that is involved in the formation of the protein. The transmembrane domain is the portion of the protein that spans the cell membrane and is involved in the regulation of the protein's localization and stability. The intracellular domain is the portion of the protein that is internal to the cell membrane and is involved in the regulation of the protein's stability and interactions with other cellular components.

IL22RA1 is involved in the regulation of various cellular processes, including immune responses, cell growth, and angiogenesis. It is a key regulator of the T cell response, which is a crucial part of the immune system. When T cells encounter an antigen that is able to activate them, the IL22RA1 protein is activated and helps to coordinate the T cell response.

IL22RA1 has also been identified as a potential drug target for various diseases. For example, it has been shown to be involved in the development and progression of skin cancer. Studies have shown that high levels of IL22RA1 are associated with the development of squamous cell carcinoma, a common type of skin cancer. Additionally, IL22RA1 has also been shown to be involved in the regulation of the immune response, which is a crucial part of the body's defense against infection and disease.

IL22RA1 has also been identified as a potential biomarker for various diseases. For example, it has been shown to be involved in the regulation of inflammation, which is a crucial part of the immune response. Studies have shown that high levels of IL22RA1 are associated with the development of various inflammatory diseases, including rheumatoid arthritis, Crohn's disease, and asthma. Additionally, IL22RA1 has also been shown to be involved in the regulation of cell growth, which is a crucial part of the development and maintenance of tissues.

In conclusion, IL22RA1 is a protein that is involved in various cellular processes throughout the body. It is a key regulator of the T cell response and has been identified as a potential drug target and biomarker for various diseases. Further research is needed to fully understand the role of IL22RA1 in the regulation of immune responses and inflammation.

Protein Name: Interleukin 22 Receptor Subunit Alpha 1

Functions: Component of the receptor for IL20, IL22 and IL24. Component of IL22 receptor formed by IL22RA1 and IL10RB enabling IL22 signaling via JAK/STAT pathways. IL22 also induces activation of MAPK1/MAPK3 and Akt kinases pathways. Component of one of the receptor for IL20 and IL24 formed by IL22RA1 and IL20RB also signaling through STATs activation. Mediates IL24 antiangiogenic activity as well as IL24 inhibitory effect on endothelial cell tube formation and differentiation

The "IL22RA1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IL22RA1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets